A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults
Completed · Phase 1 · Has a placebo group
Conditions studied: Anthrax
In brief
This study will provide preliminary safety and comparative immunogenicity data for the E.coli derived rPA vaccine administered by intramuscular (IM) injection at Day 0 and Month 1.Doses will range from 5 μg to 100 μg rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel.
Key facts
- Study ID
- NCT00057525
- Run by
- DynPort Vaccine Company LLC, A GDIT Company
- People needed
- 70
- Starts
- 2003-04-01
- Expected to finish
- 2004-08-01
- Last updated by the study team
- 2011-06-30
Who can join
Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.
Where it is running
- Walter Reed Army Institute of Research / Henry M. Jackson Foundation Vaccine Clinical Research Center, 1600 East Gude Dr — Rockville, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.